Do not use if you have ever had an allergic reaction to SITAGLIPTIN MYLAN or any of the ingredients listed at the end of the CMI. Talk to your doctor if you have any other medical conditions, take any ...
As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...
Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
Lupin has received tentative approval from the Food and Drug Administration for sitagliptin and metformin hydrochloride tablets, 50 mg/500 mg and 50 mg/1000 mg, which is a generic of Merck Sharp & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results